Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer. (PubMed, Mol Pharm) - Sep 8, 2026 - "Importantly, the full-length antibody platform enabled high-contrast visualization of pulmonary metastatic lesions and orthotopic bladder tumors despite some urinary background activity. Together, these findings demonstrate that payload-free [89Zr]Zr-DFO*-sq-Enfortumab provides a biologically relevant immunoPET platform for noninvasive assessment of variable Nectin-4 expression and support its further evaluation as a companion imaging strategy for Enfortumab Vedotin-based therapies."
Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4
|
|
Abhilash Boppana; Guiyang Hao; Jeon Lee; Jer-Tsong Hsieh; Jiawen Lang; Jue Wang; Jui Wan Loh; Li Liu; Marian N Aziz; Mickey Glover; Ningyan Zhang; Sashi Debnath; Sean Yan; Tianyuan Wang; Xiankai Sun
|